| Fecha | Hora | Fuente | Título | Símbolo | Compañía |
| 14/02/2019 | 05:43 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 16/04/2018 | 15:08 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 16/03/2018 | 07:02 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(b) (15-12b) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 07/03/2018 | 17:26 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 06/03/2018 | 07:33 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 06/03/2018 | 07:24 | Edgar (US Regulatory) | (25-NSE) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 06/03/2018 | 07:13 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 06/03/2018 | 07:02 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 05/03/2018 | 07:19 | Edgar (US Regulatory) | Amended Statement of Ownership: Private Transaction (sc 13e3/a) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 05/03/2018 | 07:13 | Edgar (US Regulatory) | Amended Statement of Ownership: Solicitation (sc 14d9/a) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 05/03/2018 | 07:03 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 05/03/2018 | 07:02 | Edgar (US Regulatory) | Amended Tender Offer Statement by Third Party (sc To-t/a) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 01/03/2018 | 15:17 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 21/02/2018 | 06:30 | Business Wire | Celgene Receives Antitrust Clearance for Juno Acquisition | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 14/02/2018 | 05:53 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 02/02/2018 | 15:50 | Edgar (US Regulatory) | Statement of Ownership: Private Transaction (sc 13e3) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 02/02/2018 | 15:44 | Edgar (US Regulatory) | Statement of Ownership: Solicitation (sc 14d9) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 02/02/2018 | 15:38 | Edgar (US Regulatory) | Tender Offer Statement by Third Party (sc To-t) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 29/01/2018 | 16:30 | Edgar (US Regulatory) | Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 25/01/2018 | 14:33 | Edgar (US Regulatory) | Written Communication Relating to an Issuer or Third Party (sc To-c) | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 24/01/2018 | 11:40 | PR Newswire (US) | WeissLaw LLP Investigates Juno Therapeutics Inc. Acquisition | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 23/01/2018 | 02:02 | Dow Jones News | Drug Firms Bet Billions on Biotech -- WSJ | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 22/01/2018 | 19:00 | Dow Jones News | Big Drugmakers Pay Big Prices for Promising Biotechs -- Update | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 22/01/2018 | 13:13 | Dow Jones News | Big Drugmakers Pay Big Prices for Promising Biotechs | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 22/01/2018 | 10:51 | PR Newswire (US) | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Juno Therapeutics, Inc. | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 22/01/2018 | 10:19 | Dow Jones News | Celgene to Buy Juno Therapeutics for $9 Billion -- 2nd Update | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 22/01/2018 | 07:49 | PR Newswire (US) | Johnson Fistel, Announces Investigations of the Proposed Sales of Bioverativ Inc., and Juno Therapeutics, Inc. | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 22/01/2018 | 06:59 | Dow Jones News | Celgene to Buy Juno Therapeutics for $9 Billion -- Update | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 22/01/2018 | 06:19 | Dow Jones News | Celgene to Buy Juno Therapeutics For $9 Billion | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |
| 22/01/2018 | 05:30 | Business Wire | Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy | NASDAQ:JUNO | Juno Therapeutics, Inc. (delisted) |